Keyword: Novartis Venture Fund
Immunitas Therapeutics is launching with $39 million in series A financing to propel at least one monoclonal antibody into the clinic.
Renovacor is working on a gene therapy for small group of patients with dilated cardiomyopathy that could spare them from a heart transplant.
Twentyeight-Seven will ramp up its cancer programs, develop programs aimed at other types of RNA and apply its work in non-oncology disease areas.
The CHF 35 million series A round sets Anaveon up to advance a preclinical asset designed to enhance anti-tumor immune responses.
Ribon Therapeutics has come out with a series B with focused on monoPARPs against cancer, inflammatory disorders and neurodegenerative diseases.
28-7 Therapeutics launched with $65 million to fund its cancer treatments that aim to increase the levels of tumor-suppressing RNA genes.
The financing tees up Enterprise to take three projects into the clinic and push one of them through a midphase proof-of-concept trial.
Vivet is harnessing the power of gene therapy to target Wilson disease and other rare genetic disorders as it looks to shake off a tough few years for research and sales in the gene therapy field.
UCSF scientist Shaun Coughlin will lead CV research at NIBR, Novo's China GM was promoted to EVP, and Cavion poached Teva exec to head up R&D.
Cavion has seen Spyridon "Spyros" Papapetropoulos join its ranks as EVP of research and development and CMO.